- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03044431
Autologous Stem Cell Treatment for Chronic Lung Disease Study
The purpose of the Lung Institute is to collect and isolate a patient's own cells and platelet rich plasma (PRP) and deliver the product back to the patient the same day. Lung Institute's treatment is limited to self-funded patients with chronic lung disease- chronic obstructive pulmonary disease (COPD) and restrictive lung diseases such as pulmonary fibrosis (PF) and interstitial lung disease (ILD). The patient's cells and platelet rich plasma are harvested through venous or bone marrow collection techniques.
The hypothesized outcomes of therapy are safety and minimization of adverse events, a perceived improvement in the patient's lung condition (to be determined by their perceived quality of life), an improvement in the FEV1 among COPD patients, the ability to reduce supplemental oxygen use, the ability to function well without the use of rescue inhalers, reduction of secondary pulmonary infections, reduction in emergency room visits and exacerbations related to their disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75231
- Lung Institute Dallas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients are included in treatment by self-referral and after consultation with a designated patient coordinator who determines initial eligibility, and then by the clinic nurse practitioner or physician of Lung Institute who determines final eligibility for inclusion. All eligible treated patients are eligible for the study.
Exclusion Criteria:
- Patients who are unable to provide informed consent, pregnant patients, prisoners, non-English speakers, patients with a history of cancer within the past 5 years, patients with active tuberculosis or pneumonia. In addition, patients on prescribed blood thinners, with a history of breast or prostate cancer of any time frame or with a history of osteoporosis are excluded from the bone marrow harvest option.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Cell therapy treated
All patients/participants enrolled will undergo cell therapy
|
Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in FEV1 From Baseline Among COPD Patients
Time Frame: Measurements pre-treatment and then at 6 months post- treatment
|
Change from baseline (among COPD patients only) as measured by pulmonary function testing/spirometry at baseline and again at 6 months post- treatment
|
Measurements pre-treatment and then at 6 months post- treatment
|
Number of Participants Reporting an Improvement in 3 Month-Post Treatment QOL Scores, All Diagnoses
Time Frame: Measurements pre-treatment and then at 3 months post-treatment for all diagnoses
|
Number of patients in the total sample who reported an improved perceived quality of life 3 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
|
Measurements pre-treatment and then at 3 months post-treatment for all diagnoses
|
Number of Participants Reporting an Improvement in 6 Month-Post Treatment QOL Scores, All Diagnoses
Time Frame: Measurements pre-treatment and then at 6 months post-treatment among all diagnoses
|
Number of patients in the total sample who reported an improved perceived quality of life 6 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
|
Measurements pre-treatment and then at 6 months post-treatment among all diagnoses
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With COPD Reporting an Improvement in 3 Month-Post Treatment QOL Scores
Time Frame: Measurements for COPD pre-treatment and then at 3 months post-treatment
|
Number of patients with a diagnosis of COPD who reported an improved perceived quality of life 3 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
|
Measurements for COPD pre-treatment and then at 3 months post-treatment
|
Number of Participants With COPD Reporting an Improvement in 6 Month-Post Treatment QOL Scores
Time Frame: Measurements for COPD pre-treatment and then at 6 months post-treatment
|
Number of patients with a diagnosis of COPD who reported an improved perceived quality of life 6 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
|
Measurements for COPD pre-treatment and then at 6 months post-treatment
|
Number of Participants With Interstitial Lung Disease Reporting an Improvement in 3 Month-Post Treatment QOL Scores
Time Frame: Measurements for ILD pre-treatment and then at 3 months post-treatment
|
Number of patients with a diagnosis of Interstitial Lung Disease who reported an improved perceived quality of life 3 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
|
Measurements for ILD pre-treatment and then at 3 months post-treatment
|
Number of Participants With Interstitial Lung Disease Reporting an Improvement in 6 Month-Post Treatment QOL Scores
Time Frame: Measurements for ILD pre-treatment and then at 6 months post-treatment
|
Number of patients with a diagnosis of Interstitial Lung Disease who reported an improved perceived quality of life 6 months post-treatment as measured by the Clinical COPD Questionnaire (CCQ).
|
Measurements for ILD pre-treatment and then at 6 months post-treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Melissa Rubio, PhD, APRN, Lung Institute Dallas
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LI001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Interstitial Lung Disease
-
Boehringer IngelheimNo longer availableLung Diseases, Interstitial (in Pediatric Populations) | Childhood Interstitial Lung Disease (chILD)
-
Matthias GrieseSuspendedInterstitial Lung Disease | Diffuse Parenchymal Lung Disease | Children´s Interstitial Lung DiseaseGermany
-
University of AlbertaAlberta Boehringer Ingelheim CollaborationNot yet recruitingFibrotic Interstitial Lung Disease
-
Monash UniversityRecruitingFibrotic Interstitial Lung DiseaseAustralia
-
Heidelberg UniversityHelmholtz Zentrum München; University of Giessen; Lungenfibrose e.V.; German Center... and other collaboratorsCompletedInterstitial Lung Disease (ILD)Germany
-
University of California, San FranciscoTerminatedFibrotic Interstitial Lung DiseaseUnited States
-
University of AarhusAarhus University HospitalNot yet recruitingProgressive Fibrosing Interstitial Lung DiseaseDenmark
-
West Virginia UniversityNot yet recruitingProgressive Fibrosing Interstitial Lung DiseaseUnited States
-
Saglik Bilimleri UniversitesiRecruitingTelerehabilitation | Fibrosing Interstitial Lung DiseaseTurkey
Clinical Trials on Cell therapy
-
Royan InstituteTehran University of Medical Sciences; Shahid Beheshti University of Medical...UnknownCovid-19Iran, Islamic Republic of
-
Nantes University HospitalUnknown
-
General Hospital of Chinese Armed Police ForcesUnknownHereditary Cerebellar Ataxia.China
-
Columbia UniversityOssium Health, Inc.RecruitingIntestinal TransplantationUnited States
-
Anhui Provincial HospitalEnrolling by invitationCirrhosis, LiverChina
-
Lung InstituteCompletedInterstitial Lung Disease | COPDUnited States
-
Ministry of Health, BrazilCompletedCoronary Artery Disease | Angina Pectoris | Chronic Ischemic Heart DiseaseBrazil
-
National Heart, Lung, and Blood Institute (NHLBI)NIH Heart Center at Suburban HospitalTerminatedCoronary Artery Disease | Ischemic Heart Disease | Heart Disease | Coronary Artery Disease (CAD)United States
-
Royan InstituteCompletedLeg Length InequalityIran, Islamic Republic of
-
Chinese Academy of SciencesNational Natural Science Foundation of China; The First Affiliated Hospital...Active, not recruitingPrimary Ovarian InsufficiencyChina